Necrostatin-1 (Synonyms: MTH-DL-Tryptophan,Nec-1) |
Katalog-Nr.GC11008 |
Ein RIP1-Kinase-Inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4311-88-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment [1]: | |
Preparation Method |
Cells were lysed, Immunoprecipitation was carried out for 16 h at 4 °C using anti-FLAG M2 agarose beads, Beads were incubated in 15 ul of the reaction buffer for 15 min at 23-25 °C in the presence of different concentrations of necrostatins (including Necrostatin-1). Kinase reaction was initiated by addition of 10 μM cold ATP and 1 μCi of [y-32P]ATP, and reactions were carried out for 30 min at 30°C. |
Reaction Conditions |
RIP1 kinase assay( Necrostatin-1) was performed at 30°C for 30 min |
Applications |
Necrostatin-1 is a RIP1 kinase inhibitor, RIP1 is the primary cellular target responsible for the antinecroptosis activity of necrostatin-1. |
Cell experiment [2]: | |
Cell lines |
Cardiomyocyte progenitor cells (CMPCs) |
Preparation Method |
CMPCs were pretreated with vehicle or Necrostatin-1 for 30 min prior to the addition of tert-Butyl hydroperoxide in serum-free M199 medium. |
Reaction Conditions |
30 µM Necrostatin-1 for 30 min |
Applications |
Under oxidative stress conditions, CMPC mainly displayed a necrotic phenotype and by pretreatment with Necrostatin-1, we observed a 37 ± 8% reduction in necrotic cell death in CMPCs compared with vehicle. Not find differences in apoptotic-mediated cell death. Therefore, Necrostatin-1 increased the survival of CMPCs by inhibiting necrotic cell death. |
Animal experiment [3]: | |
Animal models |
Eight-week-old male C57Bl/6 mice |
Preparation Method |
Mice undergo sham surgery or bilateral renal pedicle clamping 24 hours before intraperitoneal injection of either PBS, the highly specific RIP1 kinase inhibitor Necrostatin-1, or the inactive derivate of necrostatin-1 (Necrostatin-1i) in the presence or absence of RCM. |
Dosage form |
Necrostatin-1 (1.65 mg/kg body weight) was applied intraperitoneally 15 min before RCM-injection. |
Applications |
CIAKI Is Attenuated by Necrostatin-1, an Inhibitor of the Kinase Domain of Receptor-Interacting Protein Kinase-1. |
References: [1]. Degterev A, Hitomi J,et,al.Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008 May;4(5):313-21. doi: 10.1038/nchembio.83. PMID: 18408713; PMCID: PMC5434866. [2]. Feyen D, Gaetani R,et,al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013 Jul 1;99(1):83-91. doi: 10.1093/cvr/cvt078. Epub 2013 Apr 3. PMID: 23554461. [3]. Linkermann A, Heller JO,et,al. Nec-1The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013 Oct;24(10):1545-57. doi: 10.1681/ASN.2012121169. Epub 2013 Jul 5. Erratum in: J Am Soc Nephrol. 2014 Dec;25(12):2942. PMID: 23833261; PMCID: PMC3785275. |
Necrostatin-1 wirkt hauptsächlich auf RIP1 in Zellen [5]. Necrostatin-1 ist ein RIP1-Kinase-Inhibitor mit einem IC50-Wert von 0,32 mM[1]. Necrostatin-1 kann die Autophosphorylierung von RIP1 effektiv hemmen und blockiert die Signalübertragung von RIP1-RIP3-MLKL durch Hemmung der Phosphorylierung von RIP1 [7]. Necrostatin-1 ist auch ein IDO-Inhibitor[2].
Unter oxidativem Stress zeigte CMPC hauptsächlich ein nekrotisches Phänotyp und durch Vorbehandlung mit Necrostatin-1 beobachteten wir eine 37 ± 8%ige Reduktion des nekrotischen Zelltods bei CMPC im Vergleich zum Fahrzeug. Es wurden keine Unterschiede in der apoptotischen Zellsterblichkeit festgestellt. Daher erhöhte Necrostatin-1 das Überleben von CMPCs, indem es den nekrotischen Zelltod hemmte [4] . Die Verhältnisse von apoptotischen und nekrotischen C2C12-Zellen nahmen nach CoCl2-Behandlung zu, typische morphologische Merkmale der Nekroptose konnten mittels TEM beobachtet werden, während Necrostatin-1 eine schützende Wirkung gegen durch CoCl2 induzierten oxidativen Stress aufwies. Die Behandlung mit Necrostatin-1 verringerte signifikant die RIP1-, pERK1/2-, HIF 1α-, BNIP3- und ROS-Spiegel, die durch CoCl2 verursacht wurden, und förderte die Differenzierung von C2C12. Necrostatin-1 kehrte die durch CoCl2 verursachte Abnahme des mitochondrialen Membranpotentials um [6] .
Bei Mäusen verhinderte Necrostatin-1 (Nec-1), ein spezifischer Inhibitor der Kinase-Domäne des Rezeptor-interagierenden Proteins 1 (RIP1), osmotische Nephrose und CIAKI, während eine inaktive Derivat von Necrostatin-1 (Nec-1i) oder der Pan-Caspase-Inhibitor zVAD dies nicht taten. Necrostatin-1 verhinderte die RCM-induzierte Dilatation peritubulärer Kapillaren und legt nahe, dass es eine neue Rolle gibt, die nichts mit dem Zelltod zu tun hat, für die RIP1-Kinase-Domäne bei der Regulation der Mikrovaskulatur-Hämodynamik und Pathophysiologie von CIAKI[3].
References:
[1]: Xie T, Peng W, et,al. Structural basis of RIP1 inhibition by necrostatins. Structure. 2013 Mar 5;21(3):493-9. doi: 10.1016/j.str.2013.01.016. PMID: 23473668.
[2]: Degterev A, Huang Z, et,al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1(2):112-9. doi: 10.1038/nchembio711. Epub 2005 May 29. Erratum in: Nat Chem Biol. 2005 Sep;1(4):234. PMID: 16408008.
[3]: Linkermann A, Heller JO, et,al. The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013 Oct;24(10):1545-57. doi: 10.1681/ASN.2012121169. Epub 2013 Jul 5. Erratum in: J Am Soc Nephrol. 2014 Dec;25(12):2942. PMID: 23833261; PMCID: PMC3785275.
[4]: Feyen D, Gaetani R, et,al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013 Jul 1;99(1):83-91. doi: 10.1093/cvr/cvt078. Epub 2013 Apr 3. PMID: 23554461.
[5]: Degterev A, Hitomi J, et,al.Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008 May;4(5):313-21. doi: 10.1038/nchembio.83. PMID: 18408713; PMCID: PMC5434866.
[6]: Chen R, Xu J, et,al.Necrostatin-1 protects C2C12 myotubes from CoCl2-induced hypoxia. Int J Mol Med. 2018 May;41(5):2565-2572. doi: 10.3892/ijmm.2018.3466. Epub 2018 Feb 6. PMID: 29436688; PMCID: PMC5846651.
[7]: Degterev A, Huang Z, et,al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul;1(2):112-9. doi: 10.1038/nchembio711. Epub 2005 May 29. Erratum in: Nat Chem Biol. 2005 Sep;1(4):234. PMID: 16408008.
Cas No. | 4311-88-0 | SDF | |
Überlieferungen | MTH-DL-Tryptophan,Nec-1 | ||
Chemical Name | 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one | ||
Canonical SMILES | CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32 | ||
Formula | C13H13N3OS | M.Wt | 259.33 |
Löslichkeit | ≥ 12.97 mg/mL in DMSO, ≥ 13.29 mg/mL in EtOH with ultrasonic | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.8561 mL | 19.2805 mL | 38.5609 mL |
5 mM | 0.7712 mL | 3.8561 mL | 7.7122 mL |
10 mM | 0.3856 mL | 1.928 mL | 3.8561 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *